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Abstract 
Background 
Whether associations between circulating metabolites and prostate cancer are causal is 
unknown. We report on the largest study of metabolites and prostate cancer (2,291 cases and 
2,661 controls) and appraise causality for a subset of the prostate cancer-metabolite 
associations using two-sample Mendelian randomization (MR).  
Materials and Methods 
The case-control portion of the study was conducted in nine UK centres with men aged 50-69 
years who underwent prostate-specific antigen (PSA) screening for prostate cancer within the 
Prostate testing for cancer and Treatment (ProtecT) trial. Two data sources were used to 
appraise causality: a genome-wide association study (GWAS) of metabolites in 24,925 
participants and a GWAS of prostate cancer in 44,825 cases and 27,904 controls within the 
Association Group to Investigate Cancer Associated Alterations in the Genome 
(PRACTICAL) consortium.   
Results 
Thirty-five metabolites were strongly associated with prostate cancer (p <0.0014, multiple-
testing threshold). These fell into four classes: i) lipids and lipoprotein subclass 
characteristics (total cholesterol and ratios, cholesterol esters and ratios, free cholesterol and 
ratios, phospholipids and ratios, and triglyceride ratios); ii) fatty acids and ratios; iii) amino 
acids; iv) and fluid balance. Fourteen top metabolites were proxied by genetic variables, but 
MR indicated these were not causal. 
Conclusions  
We identified 35 circulating metabolites associated with prostate cancer presence, but found 
no evidence of causality for those 14 testable with MR. Thus, the 14 MR-tested metabolites 
are unlikely to be mechanistically important in prostate cancer risk. 
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Impact 
The metabolome provides a promising set of biomarkers that may aid prostate cancer 
classification. 
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Introduction 
Prostate cancer is the most frequently diagnosed malignancy among men worldwide.
1
 
Despite huge geographical variation in incidence and mortality (suggestive of environmental 
causes), the only established risk factors are age, race, and family history,
2
 while adiposity is 
associated with advanced prostate cancer.
3
 Metabolic dysregulation is a hallmark of 
carcinogenesis
4
, and various circulating metabolites have been associated with both prostate 
cancer presence and aggressiveness.
2,5–15
 However, there are limitations with the existing 
evidence-base. First, the metabolites detected as being associated with prostate cancer have 
varied between studies, with no clear pattern of associations emerging. Second, most 
previous studies have been small, having fewer than 100 cases (Supplementary Table 1 in the 
Supplement)
5
 and hence liable to the play of chance, yielding both false-positive and false-
negative findings. Third, the nature of any observed associations must be interpreted 
cautiously, because epidemiological studies are highly susceptible to various biases that 
preclude causal inference.
16,17
 For instance, metabolites may be associated with other factors 
that affect prostate cancer development (confounding), or the presence of prostate cancer may 
alter metabolites (reverse causation). Mendelian randomization (MR) is a method for 
appraising causality that uses genetic instrumental variables to proxy for exposures that can 
be otherwise confounded or subject to reverse causation. Such an approach may be used to 
distinguish causally relevant intervention targets from biomarkers that are non-causally 
associated with prostate cancer. The latter may nevertheless be of potential value in risk 
prediction (e.g. if the biomarker acts as a strong proxy for other factors leading to disease) or 
disease detection (e.g. if early disease leads to alterations in the circulating metabolome).   
Methods  
Observational study 
Study Population  
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We undertook a case-control study within the Prostate testing for cancer and 
Treatment (ProtecT) trial (ISRCTN20141297).
18–20
 During recruitment to ProtecT, 228,966 
men aged 50–69 years at 337 general practices in nine UK centres (Birmingham, Bristol, 
Cambridge, Cardiff, Edinburgh, Leeds, Leicester, Newcastle, Sheffield) were invited between 
2001 and 2009 to attend a clinic for consideration of a prostate-specific antigen (PSA) test. 
Overall, 100,444 men attended the clinic where a PSA test was offered to 82,429 men 
deemed eligible to enroll into the ProtecT treatment trial, after a fully-informed, 30-minute 
discussion with a nurse. Men with PSA levels ≥3 ng/mL were offered a 10-core diagnostic 
biopsy. Tumours were histologically confirmed, assigned a Gleason score by uropathologists, 
and clinically staged using the TNM classification.
21
 Men with a PSA <3 ng/mL or a raised 
PSA (≥3 ng/mL) but a negative biopsy without development of prostate cancer during the 
follow-up protocol were eligible as controls. Controls were randomly selected from the same 
five-year age-band (age at PSA test) and GP/family practice, as cases.
22
 
In the current analysis, in concert with the guidelines of the National Institute for 
Health and Care Excellence (NICE)
23
, men with stage T3 or T4 tumours (‘localized 
advanced’), Gleason score ≥8, or with a PSA level at diagnosis >20 ng/ml, were classified as 
‘high-risk’. Men with stage T1 or T2 tumours, Gleason score <8, or with a PSA level at 
diagnosis ≤20 ng/ml were classified as ‘low-risk’. Participants in the present analysis 
consisted of those with self-reported (White) European ancestry.  
Ethics 
All men provided written informed consent prior to inclusion into ProtecT. The Trent 
Multicentre Research Ethics Committee (MREC) approved ProtecT (MREC/01/4/025) and 
the linked ProMPT study, which collected biological material (MREC/01/4/061), including 
serum used for the present study of metabolites.  
Laboratory Analyses  
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Two hundred and twenty-seven quantified metabolic traits (henceforth “metabolites”) 
were obtained per sample of serum using a proton nuclear magnetic resonance (NMR) 
spectroscopy-based metabolomics platform (Nightingale Health, Helsinki, Finland). Details 
of the methodology have been described elsewhere.
24
 Briefly, 100 µL serum was mixed with 
sodium phosphate buffer and transferred to NMR tubes using an eight-channel, Varispan 
Janus liquid handling robot (PerkinElmer). Two 1D NMR spectra were acquired using a 500 
MHz Bruker Avance III HD spectrometer and analysed bioinformatically for 
absolute quantification of lipoprotein subclasses, their particle concentrations and 
composition, lipoprotein particle size, apolipoprotein A-I and B, multiple cholesterol and 
triglyceride measures, albumin, various fatty acids, as well as numerous low-molecular-
weight metabolites covering amino acids (including branched-chained and aromatic), 
glycolysis-related measures, and ketone bodies. The method has been widely used in 
epidemiological research and recently reviewed.
24,25
 
Statistical Analysis 
 All analyses were performed using R (version 3.4.1). Two thousand two hundred 
and ninety-one men with screen-detected prostate cancer (348 high-risk; 1939 low-risk) and 
2,661 controls had NMR metabolites measured in ProtecT. The distribution of baseline 
characteristics in cases versus controls was compared using Wilcoxon rank sum tests for 
continuous variables and a Chi-squared statistic for categorical variables. Multiple imputation 
using the ‘mice’ R package, and based on a subset of 78 metabolites chosen at random (given 
imputation constraints), was used to impute family history of prostate cancer, unknown for 
11% of participants. Family history and age were selected as covariates in multi-variable 
models of prostate cancer risk, as those factors are strongly associated with prostate cancer 
and are potential confounders of the exposure-outcome relationship. We also adjusted for the 
primary-care centre where patients were registered. Metabolite trait concentrations/ratios 
Research. 
on October 29, 2018. © 2018 American Association for Cancercebp.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on October 23, 2018; DOI: 10.1158/1055-9965.EPI-18-0079 
 13 
were log-transformed and then scaled to standard-deviation scores to allow direct comparison 
of the magnitude of the effect of traits with different units on prostate cancer. A dictionary of 
metabolic traits with units before standardization is available in Supplementary Table 2 in the 
Supplement. 
Multivariable logistic regression was performed to compare the odds of total prostate 
cancer (versus controls) per log-transformed, then standard-deviation-scaled metabolite 
concentration, such that each metabolite has a standard deviation of one. As a sensitivity 
analysis, we also examined the odds of prostate cancer by high- and low-risk case status and 
performed tests of the differences between odds ratios (took the absolute difference between 
the odds ratios (δ); calculated the standard error (SE) for δ using the SEs from each 
comparison set, such that 𝑆𝐸1
2 and 𝑆𝐸2
2 refer respectively to the SEs of the first comparison 
and second comparison sets, √𝑆𝐸1
2 + 𝑆𝐸2
2; calculated z scores, 
δ
𝑆𝐸(δ)
 ; and calculated p-values 
for the z scores) for the following comparisons: differences in odds ratios for high-risk results 
and total results, the low-risk results and total results, and high-risk and low-risk results. In 
addition (also as a sensitivity analysis) we examined the correlation between the metabolites 
and PSA, given that our population of participants was screen-(PSA) detected.  
To account for multiple testing and the correlation between the metabolic measures, 
principal component analysis was carried out on z-scored metabolic trait data.
26
 We 
calculated that the first 37 principal components explained >99% of the variance in the data 
and set our statistical threshold top < 0.05/37 (=0.0014), equivalent to p<0.05 after adjusting 
for multiple testing.  
Causal Analysis 
To assess causality, we used MR, a causal analysis method which exploits the random 
assortment of alleles in an instrumental variable (IV) framework to address confounding and 
reverse causation that preclude causal inference in observational studies.
27,28
 Germline 
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genetic variants associated with each metabolite of interest can serve as proxies (IVs) for 
those metabolites in models examining the causal effects of metabolic traits on prostate 
cancer, if a number of assumptions are met: i) the IVs (genetic variants) are robustly 
associated with metabolites; ii) the IVs are independent of confounders of the metabolites and 
prostate cancer; and iii) the IVs are not pleiotropically associated with the prostate cancer; i.e. 
they are associated with prostate cancer only through the metabolites they are instrumenting 
and not associated with prostate cancer through other exposures.
29  
From the literature, we know there are strong associations between single-nucleotide 
polymorphisms (SNPs) and metabolite levels;
30–33
 therefore, these SNPs can serve as 
instruments in Mendelian randomization analyses.
34–36
 For instance, the median proportion of 
variance explained for metabolite associations in Kettunen et al. (2016) was 5% and ranged 
from 0.2% for acetoacetate to 12.5% for glycine.
33
 To implement MR, we identified 
independent (those not in linkage disequilibrium; r2 <0.01) SNPs that were robustly 
associated at genome-wide signficance (i.e. p-value < 5x10-8) with metabolites in the 
Kettunen et al. (2016) genome-wide association study (GWAS) of 123 circulating 
metabolites in 24,925 participants from 14 European cohorts.
33
 These SNPs were chosen as 
IVs for our metabolites. We could not instrument 113 of the 227 NMR-quantified metabolic 
traits; sixty five of these traits were ratio measures not included in the GWAS and 48 were 
other types of traits that had no genetic proxy.  
To leverage power from large samples, we performed two-sample MR,
27,37,38
 whereby 
we obtained summary data on the effects of the SNPs that acted as genetic instruments for 
each metabolite on prostate cancer from a separate data source, the Prostate Cancer 
Association Group to Investigate Cancer Associated Alterations in the Genome 
(PRACTICAL) consortium. This consortium involved 52 prostate cancer case-control studies 
on which genome-wide association studies (GWAS) had been conducted.
39–44
 The current 
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MR analysis was based on 44,825 prostate cancer cases and 27,904 controls from within 48 
of the 52 PRACTICAL cohorts of men with European ancestry.  
To implement MR, we undertook the following process for each of the SNPs 
identified as a proxy for each metabolite: we extracted the effect and non-effect allele, and 
the log odds ratio (OR) and standard error per copy of the effect allele from the PRACTICAL 
GWAS. We used these data to construct our genetic instruments for our circulating metabolic 
traits and calculated the log OR for prostate cancer per standard deviation (SD) increase in 
metabolic measure levels using the two-sample MR Maximum likelihood estimator.
45
 
(Supplementary Table 3 in the Supplement contains the characteristics of the genetic variants 
associated with metabolites that were selected as instruments.) In computing the effect 
estimates based on MR, the effect estimates for each SNP-prostate cancer association were 
meta-analysed.  
Two-sample MR analyses were performed in R using the TwoSampleMR package
46
. 
Results 
Characteristics of men in the ProtecT study 
 Table 1 compares the distribution of selected characteristics in cases versus controls. 
The median age (63 years) and body mass index (BMI, 27 kg/m2) were the same, but more 
cases than controls had a family history of prostate cancer (8% versus 5%; p <0.001).   
Observational associations of metabolic traits on prostate cancer (ProtecT) 
Thirty-five metabolites were associated with odds of prostate cancer at p <0.0014 
(Table 2, Figure 1, and Supplementary Table 4 in the Supplement). The following increased 
the odds of prostate cancer: i) Lipids and lipoprotein particle concentration, specifically, total 
lipids (TL) in small high-density lipoprotein (HDL) and concentration of small HDL 
particles; ii) Total cholesterol (TC) and TC compositional ratios, namely, TC in HDL3, TC in 
medium low-density lipoprotein (LDL), small HDL, and small LDL; and TC:TL ratios in 
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medium LDL, small HDL, small LDL, and small very low-density lipoprotein (VLDL); iii) 
Cholesterol esters (CE) and CE compositional ratios, specifically: CE in medium LDL, small 
HDL, and small LDL; CE-to-TL ratios in medium LDL, CE:TL ratios in small HDL and 
small LDL; iv) Free cholesterol (FC) and a FC compositional ratios, namely, FC in IDL, 
large LDL, and medium HDL, and FC-to-TL ratio in medium HDL; v) Phospholipids (PL) 
and PL compositional ratios, including: PL in intermediate-density lipoprotein (IDL) and 
very small VLDL, and PL:TL ratios in medium VLDL and very small VLDL; vi) and the 
protein albumin; vii) the ratio of omega-6 fatty acids (FA) to total FA. 
The following decreased the odds of total prostate cancer: VLDL particle size, PL-to-
TL ratios in medium LDL; triglycerides (TG)-to-total lipid ratios in small and medium 
VLDL; amino acids (AA), specifically, the branched-chain AA, isoleucine, leucine, and 
valine, and the aromatic AA tyrosine; and saturated FA-to-total FA.  
In the sensitivity analysis of the effect of metabolic traits on high-risk prostate cancer 
versus controls, albumin was associated with high-risk case status (OR 1.12; 95% CI 1.08-
1.36; p<0.0014); 138 (61%) had ORs reversed from those in the combined (total, case-
control) analysis; and, though 53 ORs were statistically different from those in the total 
analysis (p-value threshold <0.05), none of the differences survived multiple comparisons 
(p<0.05/227; 0.0002). (Supplementary Tables 5 and 6 in the Supplement). Consistent with 
these results, in the comparison of high-versus low-risk ORs, 78 metabolites had ORs that 
were statistically different at the <0.05 threshold and two at the multiple-testing threshold (p-
value <0.0002: TC:TL in small HDL and PL:TL in small HDL); 63% of metabolites had 
directionally reversed ORs. Notably, among the 35 top metabolites in the total analysis, eight 
were included in the set of those with statistically different ORs in the high- versus low-risk 
comparison (p-value for multiple testing set to 0.05/35=0.0014) (Supplementary Tables 7 and 
8 in the Supplement). Conversely, the sensitivity analysis for the effect of metabolites on 
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low-risk prostate cancer (versus controls) revealed patterns of association that mirrored the 
magnitude and direction of effects observed for the total analysis versus controls; only four 
(0.02%) metabolites in the low-risk analysis had ORs directionally reversed from those in the 
total analysis; and none of the ORs were statistically different from those in the total analysis 
(p-value <0.05) (Supplementary Tables 9 and 10 in the Supplement).  
None of the metabolite-PSA correlations exceeded |0.06| (Supplementary Table 11 in 
the Supplement).   
Mendelian randomization causal analysis (PRACTICAL) 
Fourteen of the top 35 metabolites observationally associated with total prostate 
cancer were analysable using MR. Of the 14 metabolites that were instrumental, none appear 
causal for prostate cancer risk (Figure 2, Supplementary Table 12 and 13 in the Supplement).  
Discussion 
Main findings 
We identified 35 potential biomarkers for prostate cancer. The majority of these were 
cholesterols, followed by glycerides and phospholipids. Steroid hormones, including 
androgens that drive prostate cancer, are derived from cholesterol,
47
 and high levels of 
cholesterol are required by rapidly proliferating cells.
48
 Hence, it is possible that our findings 
point to the underlying relationship between prostate cancer and androgens. Moreover, the 
observed effects appear to be driven solely by the low-risk cases, which were more abundant 
in our screen-detected cohort. The weak correlations between the metabolites and PSA 
suggest that our findings are not a bi-product of screening.  
Fifteen of the top non-instrumented metabolites were ratios, which means that we 
were able to test the causal effects for the majority (70%) of our top metabolites that were not 
ratios (14/20). 
Comparison with previous literature  
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A few recent studies have explored the relationship between serum metabolites and 
prostate cancer using metabolites detected from chromatography-mass spectrometry.
2,14,15
 In 
a pilot study, Mondul et al. (2014) compared 420 metabolic compounds in fasting serum 
collected prospectively from 74 clinically detected prostate cancer cases and 74 matched 
controls within the Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study (ATBC) 
cohort. In their study, circulating 1-stearoylglycerol (1-SG) was inversely associated with 
prostate cancer (OR 0.34, 95% CI 0.20-0.58).
15
 In the present study, we did not quantify 1-
SG. In their replication study, also within the ATBC cohort, Mondul et al. (2015) analysed 
fasting serum collected prospectively for 626 metabolic compounds in 200 clinically detected 
cases and 200 matched controls.
14
 Notably, there was no overlap between the findings of the 
present study and those of Mondul et al. (2015).
14
 
Similarly, Huang et al. (2016) undertook an investigation of prostate cancer within the 
Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial (PLCO), for which they 
prospectively examined 695 known serum metabolites in 380 screen-detected cases and 380 
matched controls. Their set of top metabolites differed from both from ours and the set 
observed in the ATBC (clinically detected) studies.
2
  
The present study differed from both the two ATBC and the PLCO metabolome 
studies—studies perhaps the most comparable to ours— in that, instead of using 
chromatography-mass spectrometry to detect agnostically any measurable serum metabolites, 
we used a quantitative high-throughput NMR metabolomics platform with a pre-chosen set of 
metabolites that cover metabolic pathways for lipoprotein lipids and subclasses, fatty acids, 
amino acids, and glycolysis precursors. As such, some of the deviation between our findings 
and theirs are explained by this—we examined different sets of metabolites. Another 
difference is that the ATBC and PLCO studies were prospective and the observational 
portion of the present study is cross-sectional.  
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We observed a family history of prostate cancer in 8% of cases, likely reflecting that 
they were identified in a screening versus a clinical setting. 
Strengths   
Our analysis uses MR to interrogate whether some of our top findings (those with 
genetic instruments) appear causal. It is the first study of circulating metabolic traits and 
prostate cancer to do so. Moreover, it is the largest (more than 4x larger than the largest 
previous study
2
) examination of the role of circulating metabolites in prostate cancer, and it 
yielded novel and promising associations with metabolic traits that may be useful clinically 
as biomarkers to better distinguish presence of disease and disease severity.  
Limitations  
Our study has a few limitations. As the blood samples were collected at diagnosis for 
cases, we were unable to determine the direction of causality in our observational analyses. 
Likewise, there is potential, due to the way we selected our controls [men with PSA <3 
ng/mL or a raised PSA (≥3 ng/mL) and negative biopsy] for there to be some 
misclassification of case status. Use of MR, at least for the instrumentable metabolites, 
allowed us, nonetheless, to appraise causality for a subset of our top findings, and we had at 
least 80% power to detect effect estimates within the range of those observed in our 
observational analysis for most metabolites. Another limitation is that there was a lack of 
specificity for many of the available genetic instruments, potentially biasing our causal 
analysis towards the null. Given this, while our MR found no evidence for causality, future 
MR analyses containing a larger number of specific genetic instruments for the metabolites 
are needed to strengthen causal assessment of the role of the metabolites we have detected as 
marking the presence of prostate cancer.  
Conclusion  
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We identified 35 circulating metabolites associated with prostate cancer presence, but 
found no evidence of causality for those 14 testable with MR. Thus, the 14 metabolites tested 
with MR are unlikely to be mechanistically important in prostate cancer risk. We cannot 
speculate about the causality for those not tested with MR.  
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Table 1. Baseline characteristics (medians and interquartile ranges, or percents) for ProtecT 
cases and controls 
Characteristic Case (n=2291) 
Control 
(n=2661) P-value
1 
Age 63                                 
(59-67) 
63                             
(59-66) 
0.709 
Family history of prostate cancer              
(%)
2
 
170                                          
(8) 
128                               
(5) 
<0.001 
BMI (kg/m
2
) 
27                             
(24-29) 
27                  
(24-29) 
0.872 
ProtecT=Prostate Testing for Cancer and Treatment trial. 
1
P-value based on Chi-squared tests (for categorical variables) and Wilcoxon rank sum tests 
(for continuous variables). 
2
Family history data available on only 90% of these subjects. 
3
BMI data available on only 64% of these subjects. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2. Among ProtecT cases and controls, odds of prostate cancer for top metabolites
1 
Name OR LCI UCI P-value
2 
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Lipids and Lipoprotein Subclass 
Characteristics 
    Small HDL (particle concentration) 1.102 1.042 1.167 0.00070 
VLDL (mean particle diameter) 0.906 0.856 0.958 0.00056 
     Cholesterol Esters (CE) 
    CE in medium LDL  1.105 1.044 1.170 0.00058 
CE to total lipids ratio in medium LDL  1.108 1.044 1.180 0.00062 
CE in small HDL 1.135 1.071 1.205 0.00002 
CE to total lipids ratio in small HDL  1.100 1.038 1.167 0.00111 
CE in small LDL  1.099 1.039 1.165 0.00107 
CE to total lipids ratio in small LDL  1.100 1.037 1.169 0.00139 
     Free (FC) & Total Cholesterol (TC) 
    FC in IDL  1.105 1.044 1.170 0.00057 
FC in large LDL  1.101 1.041 1.166 0.00080 
FC in medium HDL  1.109 1.045 1.179 0.00060 
FC to total lipids ratio in medium HDL 1.109 1.045 1.179 0.00055 
TC in HDL3  1.098 1.038 1.162 0.00109 
TC in medium LDL 1.100 1.039 1.164 0.00095 
TC to total lipids ratio in medium LDL    1.100 1.039 1.167 0.00105 
TC in small HDL 1.144 1.080 1.213 <0.00001 
TC to total lipids ratio in small HDL   1.099 1.039 1.165 0.00106 
TC in small LDL 1.097 1.037 1.161 0.00132 
TC to total lipids ratio in small LDL  1.100 1.039 1.166 0.00107 
TC to total lipids ratio in small VLDL 1.099 1.038 1.163 0.00105 
     Phospholipids (PL) & Total Lipids (TL) 
    PL in IDL  1.100 1.040 1.164 0.00092 
PL to total lipids ratio in medium LDL 0.904 0.853 0.957 0.00046 
PL to total lipids ratio in medium VLDL 1.145 1.082 1.211 <0.00001 
PL in very small VLDL 1.099 1.039 1.163 0.00103 
PL to total lipids ratio in very small VLDL 1.120 1.056 1.190 0.00013 
TL in small HDL 1.108 1.048 1.173 0.00035 
     Triglycerides (TG) 
    TG to total lipids ratio in medium VLDL 0.907 0.857 0.959 0.00064 
TG to total lipids ratio in small VLDL 0.906 0.856 0.958 0.00055 
Fatty Acids (FA) 
    Ratio of omega-6 FA to total FA 1.102 1.041 1.166 0.00080 
Ratio of saturated FA to total FA 0.890 0.841 0.942 0.00006 
Amino Acids 
    Isoleucine  0.893 0.844 0.944 0.00008 
Leucine 0.901 0.851 0.953 0.00027 
Tyrosine 0.886 0.837 0.937 0.00003 
Valine  0.913 0.863 0.965 0.00139 
Fluid Balance 
    Albumin  1.104 1.043 1.168 0.00065 
ProtecT=Prostate Testing for Cancer and Treatment trial; OR=odds ratio; LCI=lower limit of 
95% confidence interval; UCI=upper limit of 95% confidence interval; HDL= high-density 
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lipoprotein; LDL=low-density lipoprotein; VLDL=very low-density lipoprotein; 
IDL=intermediate-density lipoprotein. 
 
1
Models adjusted for age, centre, and imputed family history of prostate cancer (imputed 
because family history was only available for 90% of subjects).  
2
P-value threshold corrected for multiple testing (P<0.05/37=0.0014).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figures and Legends  
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Figure 1. Volcano plot of the odds of prostate cancer in ProtecT.  
 
Figure 1 displays a volcano plot of the odds of prostate cancer in ProtecT (Prostate Testing 
for Cancer and Treatment trial). OR=odds ratio. Labelled metabolites are Bonferroni 
significant (<0.05/227). Light-grey dots indicate p-value <0.0014; dark-grey dots indicate p-
value <0.05; and medium-grey dots indicate p-value>=0.05.  
 
 
Figure 2. Forest plot showing odds of prostate cancer by metabolite for top observational 
findings in ProtecT along with causal estimates from Mendelian randomization.   
 
Figure 2 is a forest plot of the odds of prostate cancer by metabolite for top observational 
findings in the Prostate Testing for Cancer and Treatment (ProtecT) trial with models 
adjusted for age, centre, and imputed family history of prostate cancer. Summary data for the 
effects of metabolite loci on prostate cancer for the Mendelian randomization analysis was 
obtained from the Prostate Cancer Association Group to Investigate Cancer Associated 
Alterations in the Genome (PRACTICAL) consortium. The squares and lines indicate odds 
ratios and 95% confidence intervals for top findings in ProtecT. The circle dots and lines 
indicate the causal estimates for the effects of the metabolites on prostate cancer in 
PRACTICAL. 
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